Clinical Effects of Botulinum Toxin Type A Combined With Extracorporeal Shockwave Therapy on Plantar Flexor Spasticity in Cerebral Palsy
İsmail Hakan Akbulut, Belgin Erhan
Istanbul Medeniyet University
阅读操作
确认中在文库中上传 PDF 后可生成中文音频讲解。
摘要与影响
OBJECTIVE: To compare Botulinum Toxin Type A (BoNT-A) alone versus BoNT-A combined with extracorporeal shockwave therapy (ESWT) on spasticity, functional mobility, pain, and range of motion in children with spastic cerebral palsy (CP). DESIGN: Single-blind randomized controlled trial of 20 children with spastic CP. All participants received BoNT-A injections into the ankle plantar flexors; the combination group additionally received three weekly ESWT sessions. Spasticity (MAS, MTS), functional mobility (MTUG), pain (FPS-R), and passive ankle dorsiflexion range of motion (PROM) were assessed at baseline and follow-up. RESULTS: At 12 weeks, the primary endpoint (MAS* of the plantar flexor muscle with the highest baseline MAS score) was numerically lower with BoNT-A plus ESWT than with BoNT-A alone, although the between-group difference was not statistically significant. Between-group differences in MTS, MTUG, FPS-R, and PROM were also nonsignificant. Sustained within-group improvements in spasticity, functional mobility, and pain were observed with combined treatment, although these findings did not establish superiority. CONCLUSION: Combined BoNT-A and ESWT was associated with sustained improvements in several clinical outcomes; however, superiority over BoNT-A alone was not demonstrated for the primary endpoint. Larger trials are warranted to investigate the potential additional benefits of ESWT.
逐年被引趋势
暂无年度引用数据
关键指标
同类平均 = 1
同领域 · 同年份 · 同类型
Google Scholar 与 OpenAlex 的被引统计范围不同,数值存在差异属正常。
AI 辅助阅读
依据:摘要
可就本文提问;依据不足时会说明。
学术脉络
学科主题
生物医学Botulinum Toxin and Related Neurological Disorders
Cerebral Palsy and Movement Disorders · Neurogenetic and Muscular Disorders Research